Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in Cardiorenal Syndrome
NCT00532688Phase 3Unknown
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in cardiorenal syndrome (CRS), heart failure (HF) and kidney failure (2 arms). Primary endpoints: Vascular function via non invasive ultrasound measured flow mediated dilatation at 9 weeks and Estimated glomerular filtration rate at 9 weeks. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
cardiorenal syndrome (CRS)heart failure (HF)kidney failure
Beyond the preview
Go deeper on NCT00532688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532688.